On July 25th, Gelon Hui announced that Gu Sheng Tang (02273.HK) is expected to record revenue of approximately RMB 133.1 million to RMB 138.1 million in the first half of 2024, an increase of approximately 35% to 40% compared to the revenue of RMB 98.61 million for the six months ended June 30, 2023. The net profit for the first half of 2024 is expected to be approximately RMB 10.3 million to RMB 10.8 million, an increase of approximately 11% to 16% compared to the net profit of RMB 9.32 million for the first half of 2023. The adjusted net profit for the first half of 2024 is expected to be approximately RMB 14.4 million to RMB 14.9 million, an increase of approximately 41% to 46% compared to the adjusted net profit of RMB 10.18 million for the first half of 2023.

The board of directors believes that the increase in revenue, net profit, and adjusted net profit (defined by the Group as the net profit after deducting the equity-based payments settled in equity and share-based rewards granted in relation to the pre-IPO share option scheme approved and adopted by the Company on March 31, 2021, the restricted share award scheme (existing shares) adopted by the board of directors on September 9, 2022, and the share option plan and restricted share award scheme (new shares) adopted by the Company on December 7, 2022) is mainly due to the increase in the number of customers visiting the company's existing offline medical institutions (attributable to the company's continuous efforts to provide comprehensive and high-quality traditional Chinese medical health services, which has resulted in widespread recognition of the company's Gu Sheng Tang brand) and the company's business expansion, including the increase in the number of physicians in the company's online medical and healthcare platform and offline medical institutions, as well as the growth in the number and geographic coverage of the company's offline medical institutions.